These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 20498331)

  • 1. Molecular therapeutic strategies targeting Duchenne muscular dystrophy.
    Mendell JR; Rodino-Klapac LR; Malik V
    J Child Neurol; 2010 Sep; 25(9):1145-8. PubMed ID: 20498331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.
    Aartsma-Rus A; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S71-7. PubMed ID: 12206800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Frontline studies on Duchenne muscular dystrophy treatment].
    Matsuo M
    No To Hattatsu; 2009 Mar; 41(2):92-5. PubMed ID: 19517771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic treatments in muscular dystrophies.
    Muntoni F; Wells D
    Curr Opin Neurol; 2007 Oct; 20(5):590-4. PubMed ID: 17885450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the treatment of Duchenne muscular dystrophy.
    Rodino-Klapac LR; Mendell JR; Sahenk Z
    Curr Neurol Neurosci Rep; 2013 Mar; 13(3):332. PubMed ID: 23328943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical studies for gene therapy of Duchenne muscular dystrophy.
    Odom GL; Banks GB; Schultz BR; Gregorevic P; Chamberlain JS
    J Child Neurol; 2010 Sep; 25(9):1149-57. PubMed ID: 20498332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of exon skipping for treatment for Duchenne muscular dystrophy.
    Partridge T
    J Child Neurol; 2010 Sep; 25(9):1165-70. PubMed ID: 20519674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy.
    Yokota T; Pistilli E; Duddy W; Nagaraju K
    Expert Opin Biol Ther; 2007 Jun; 7(6):831-42. PubMed ID: 17555369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mutation-specific treatments for Duchenne muscular dystrophy].
    Matsuo M; Takeshima Y
    Brain Nerve; 2009 Aug; 61(8):915-22. PubMed ID: 19697880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contributions of Japanese patients to development of antisense therapy for DMD.
    Matsuo M; Takeshima Y; Nishio H
    Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exon skipping: a first in class strategy for Duchenne muscular dystrophy.
    Niks EH; Aartsma-Rus A
    Expert Opin Biol Ther; 2017 Feb; 17(2):225-236. PubMed ID: 27936976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of novel therapeutic approaches for Duchenne muscular dystrophy].
    Takeshima Y
    No To Hattatsu; 2014 Mar; 46(2):109-14. PubMed ID: 24738186
    [No Abstract]   [Full Text] [Related]  

  • 14. New developments in the use of gene therapy to treat Duchenne muscular dystrophy.
    Jarmin S; Kymalainen H; Popplewell L; Dickson G
    Expert Opin Biol Ther; 2014 Feb; 14(2):209-30. PubMed ID: 24308293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic therapeutic approaches for Duchenne muscular dystrophy.
    Foster H; Popplewell L; Dickson G
    Hum Gene Ther; 2012 Jul; 23(7):676-87. PubMed ID: 22647146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duchenne muscular dystrophy: an updated review of common available therapies.
    Salmaninejad A; Valilou SF; Bayat H; Ebadi N; Daraei A; Yousefi M; Nesaei A; Mojarrad M
    Int J Neurosci; 2018 Sep; 128(9):854-864. PubMed ID: 29351004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurology Care, Diagnostics, and Emerging Therapies of the Patient With Duchenne Muscular Dystrophy.
    Leigh F; Ferlini A; Biggar D; Bushby K; Finkel R; Morgenroth LP; Wagner KR
    Pediatrics; 2018 Oct; 142(Suppl 2):S5-S16. PubMed ID: 30275245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Less is more: therapeutic exon skipping for Duchenne muscular dystrophy.
    Aartsma-Rus A; van Ommen GJ
    Lancet Neurol; 2009 Oct; 8(10):873-5. PubMed ID: 19713153
    [No Abstract]   [Full Text] [Related]  

  • 19. Non-viral gene therapy for Duchenne muscular dystrophy: progress and challenges.
    Rando TA
    Biochim Biophys Acta; 2007 Feb; 1772(2):263-71. PubMed ID: 17005381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular treatments in Duchenne muscular dystrophy.
    Guglieri M; Bushby K
    Curr Opin Pharmacol; 2010 Jun; 10(3):331-7. PubMed ID: 20434401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.